YOLFTbeta
Pharmicell

Pharmicell

005690 · KO · Healthcare / Biotechnology

8,670.00KRW+90.00 (+1.05%)

Price History

Full chart

Market Stats

Previous Close8,580.00
Open8,660.00
Day Range8,630.00 – 9,100.00
52-Week Range8,140.00 – 21,150.00
Volume655.60K
Market Cap755.45B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.41%
Beta0.64
50-Day Avg11,196.80
200-Day Avg14,162.15

About

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hyun-Soo Kim
  • Employees0
  • HeadquartersSsangbong Building, Seoul, South Korea, Korea
  • Websitehttps://www.pharmicell.com

Leadership

  • Mr. Hyun-Soo KimCEO & Chairman of the Board of Director · b. 1964
  • Mr. HeeCheol JeongMD, Internal Accounting Manager & Controller · b. 1964
  • Mr. Gil Su JeongMD, Head of Biomedical Division & Director · b. 1976

Financials

Income Statement

Currency: KRW2010-12-312011-12-312012-12-312013-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.22B10.28B11.11B33.41B27.84B25.20B28.35B32.48B37.75B51.81B60.18B56.23B64.85B114.06B
Growth (%)-+42.47%+8.07%+200.63%-16.66%-9.49%+12.52%+14.57%+16.22%+37.24%+16.16%-6.57%+15.34%+75.88%
Cost of Revenue6.22B11.94B9.85B24.73B17.62B17.13B16.55B19.45B19.97B28.10B36.36B40.74B43.52B63.38B
Gross Profit993.69M-1.66B1.26B8.68B10.22B8.07B11.80B13.03B17.78B23.71B23.82B15.49B21.33B50.68B
Gross Margin13.77%-16.15%11.32%25.97%36.70%32.02%41.63%40.12%47.09%45.76%39.58%27.55%32.89%44.43%
Operating Expense11.47B13.72B15.51B16.52B12.08B12.53B11.54B11.07B10.55B15.84B14.95B14.20B16.67B16.37B
Operating Income-10.48B-15.38B-14.25B-7.85B-1.87B-4.46B260.18M1.96B7.23B7.86B8.87B1.30B4.66B34.30B
Operating Margin-145.16%-149.57%-128.24%-23.49%-6.70%-17.70%0.92%6.05%19.16%15.18%14.74%2.30%7.18%30.08%
EBITDA------1.13B-11.00B4.34B7.10B12.93B8.90B8.44B9.43B37.95B
EBITDA Margin------4.50%-38.80%13.35%18.80%24.96%14.79%15.01%14.54%33.27%
Net Income-11.86B-18.17B-17.64B-25.70B-676.71M-39.20B-12.68B4.35B5.24B9.45B8.26B3.58B6.33B40.29B
Net Income Margin-164.31%-176.74%-158.77%-76.94%-2.43%-155.56%-44.73%13.38%13.88%18.24%13.73%6.36%9.76%35.32%
R&D366.60M366.60M418.36M762.26M2.73B3.60B4.51B4.87B4.31B6.99B6.88B6.54B7.89B6.71B
R&D as % of Total Revenue5.08%3.57%3.77%2.28%9.82%14.30%15.89%15.00%11.41%13.50%11.44%11.64%12.16%5.89%
Interest Expense00000056.76M101.30M84.89M1.68B746.20M866.88M101.37M145.25M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.20%0.31%0.22%3.25%1.24%1.54%0.16%0.13%

Balance Sheet

Currency: KRW2010-12-312011-12-312012-12-312013-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets29.74B101.15B136.43B99.37B101.95B63.75B59.12B63.27B69.74B94.33B109.65B92.52B99.26B157.17B
Total Liabilities19.84B18.33B34.84B16.95B7.36B7.76B11.63B11.75B12.64B30.46B32.98B12.12B12.83B33.30B
Total Equity9.92B82.85B101.62B82.46B94.60B55.99B47.49B51.52B57.11B63.87B76.66B80.40B86.44B123.88B
Cash8.19B3.59B11.01B1.63B11.85B13.02B18.59B16.70B20.94B26.21B14.36B13.72B8.26B28.85B
Net Debt----------2.32B---

Cash Flow

Currency: KRW2010-12-312011-12-312012-12-312013-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.41B-16.17B-11.87B-2.69B988.97M-2.01B3.40B-75.50M8.98B-5.22B7.91B11.81B3.50B41.05B
Investing Cash Flow-6.55B-890.53M-7.20B9.04B----------
Financing Cash Flow15.14B12.45B26.49B-15.74B----------
Capital Expenditure531.05M664.72M2.48B478.99M3.85B4.27B4.68B1.66B742.73M4.32B18.96B6.02B4.34B7.49B
Free Cash Flow------6.28B-1.27B-1.74B8.24B-9.54B-11.04B5.79B-839.98M33.56B
Dividends Paid-------------1.20B
FCF to OCF-----312.87%-37.37%2301.69%91.73%182.73%-139.53%49.03%-24.01%81.75%
Dividend Paid to FCF-------------3.58%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Feb 12, 2015May 15, 2015Aug 13, 2015Nov 13, 2015Feb 11, 2016May 12, 2016Aug 12, 2016Nov 9, 2016Feb 9, 2017May 12, 2017Aug 11, 2017Nov 14, 2017Feb 12, 2018May 16, 2018Aug 14, 2018Nov 14, 2018Feb 11, 2019May 9, 2019Aug 11, 2019Nov 12, 2019Jan 27, 2020May 12, 2020Aug 12, 2020Nov 10, 2020Feb 7, 2021May 10, 2021Aug 16, 2021Nov 8, 2021Mar 15, 2022May 9, 2022Aug 15, 2022Nov 20, 2022Feb 5, 2023May 15, 2023Aug 11, 2023Nov 8, 2023Mar 20, 2024May 14, 2024Aug 13, 2024Nov 5, 2024Feb 10, 2025May 8, 2025Aug 11, 2025Nov 4, 2025Mar 18, 2026May 11, 2026Aug 19, 2026
EPS Estimate--------------------------------------------------------------------203.00-
EPS Actual-65.8019.86-219.351.36-75.36-106.20-211.17-255.82-91.34-148.35-185.19-215.09-104.26-105.97-79.32-176.03-35.07-68.8441.74-546.00-53.51-72.03-44.78-454.00-37.03-19.65-25.01-34.00-4.89-13.2812.15-5.81-21.38-26.74-9.51-613.60-9.14-6.72-4.54-191.4816.5418.82-1.7139.3014.0050.0012.0011.4531.6036.2659.6431.2082.2437.2664.64-2.5611.659.5917.8420.55-22.7447.1311.9069.23140.93123.07146.26261.18194.80172.96
Surprise---------------------------------------------------------------------4.04%-
Timing-----------------------After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market-After-hours-

Key Statistics & Ratios

Market Cap755.45B
Enterprise Value712.31B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales31.55
Price / Book5.25
Revenue (TTM)23.94B
Gross Profit (TTM)5.45B
EBITDA-6.18B
Profit Margin-111.85%
Operating Margin-85.95%
Return on Equity-29.25%
Return on Assets-4.98%
Shares Outstanding60.00M
Shares Float39.84M
Beta0.64
Dividend Yield0.41%
Dividend Rate50.00
Payout Ratio6.45%

Dividends

20251×
50.00Dec 29, 2025
20241×
20.00Dec 27, 2024
19971×
21.84Jan 3, 1997
19961×
21.84Jan 3, 1996

Stock Splits

  • Dec 19, 201110:1